Targeted Therapies for AML Ravandi, Farhad Ravandi, Farhad Less Oncology Times. 40(10):5-7, May 20, 2018. Favorites PDF Get Content & Permissions
Renegade Cells Foretell Relapse in Children With Leukemia Less Oncology Times. 40(8):1,15-15, April 20, 2018. Favorites PDF Get Content & Permissions
RAI Following Thyroid Cancer Surgery Increases Risk for AML & CML Holt, Chuck Holt, Chuck Less Oncology Times. 40(7):18-19, April 5, 2018. Favorites PDF Get Content & Permissions
ALL Patients May Do Better When Treated Early With CAR-T Therapy Less Oncology Times. 40(7):1-5, April 5, 2018. Favorites PDF Get Content & Permissions
Prevalence of Cognitive Decline Among Elderly Patients With Hematologic Cancers Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(7):1,7-7, April 5, 2018. Favorites PDF Get Content & Permissions
Utilizing iPS Cells to Advance Leukemia Research Via Human Models Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 40(5):26-27, March 5, 2018. Favorites PDF Get Content & Permissions
A Genetic Fault That Reduces Effectiveness of Leukemia Treatment Less Oncology Times. 40(5):1,13-13, March 5, 2018. Favorites PDF Get Content & Permissions
Obinutuzumab Plus Venetoclax Induces Deep Durable Responses in CLL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):32, February 5, 2018. Favorites PDF Get Content & Permissions
Combination of Ibrutinib & Venetoclax Shows Promise in Previously Treated CLL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):30, February 5, 2018. Favorites PDF Get Content & Permissions
Venetoclax-Rituximab Combo Outperforms Standard Chemo in Refractory CLL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):28, February 5, 2018. Favorites PDF Get Content & Permissions
Genomics in Chronic Lymphocytic Leukemia: Current Research & Future Implications May, Brandon May, Brandon Less Oncology Times. 40(3):1,16-17, February 5, 2018. Favorites PDF Get Content & Permissions
AML Study Reports High Response Rates With Combo Targeted Therapy Less Oncology Times. 40(1):10, January 5, 2018. Favorites PDF Get Content & Permissions
New Drug Target Discovered for Acute Myeloid Leukemia Less Oncology Times. 39(24):41, December 25, 2017. Favorites PDF Get Content & Permissions
Management of Older Patients With Chronic Lymphocytic Leukemia Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(23):32, December 10, 2017. Favorites PDF Get Content & Permissions
Shift in Plans Results in Groundbreaking Work Toward Novel Therapies for AML Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 39(23):11-12, December 10, 2017. Favorites PDF Get Content & Permissions
First-Line Treatment Options for CLL Wierda, William G. Wierda, William G. Less Oncology Times. 39(21):1,17-17, November 10, 2017. Favorites PDF Get Content & Permissions
Rituximab/Hyaluronidase (Rituxan Hycela™) Melaragno, Adam Melaragno, Adam Less Oncology Times. 39(20):18, October 25, 2017. Favorites PDF Get Content & Permissions
ALL in Older Adults: Novel Treatment Modalities Yilmaz, Musa; Kantarjian, Hagop; Jabbour, Elias Yilmaz, Musa; Kantarjian, Hagop; Jabbour, Elias Less Oncology Times. 39(20):1,11-16, October 25, 2017. Favorites PDF Get Content & Permissions
CAR T-Cell Therapy: The New Frontier of Hope Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 39(20):1,6,7,31-31, October 25, 2017. Favorites PDF Get Content & Permissions
New Treatment Approved for Relapsed or Refractory ALL Less Oncology Times. 39(18):29, September 25, 2017. Favorites PDF Get Content & Permissions
Chemo-Boosting Drug Discovered for Leukemia Less Oncology Times. 39(18):1,10-10, September 25, 2017. Favorites PDF Get Content & Permissions
Debate: Should CLL Patients Be Treated Early With Novel Agents? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(13):22, July 10th, 2017. Favorites PDF Get Content & Permissions
Dasatinib Excels in Worldwide Phase II Trial Against Pediatric CML Less Oncology Times. 39(13):33, July 10th, 2017. Favorites PDF Get Content & Permissions
CAR T-Cell Therapy Granted Priority Review for B-Cell ALL Less Oncology Times. 39(12):31, June 25th, 2017. Favorites PDF Get Content & Permissions
The Role of STAT3 in CLL Rozovski, Uri; Estrov, Zeev Rozovski, Uri; Estrov, Zeev Less Oncology Times. 39(12):12, June 25th, 2017. Favorites PDF Get Content & Permissions
Newer CLL Agents Require Specific Management Techniques Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(12):1,8-9, June 25th, 2017. Favorites PDF Get Content & Permissions
CAR T-Cell Therapy Response in Leukemia Patients Less Oncology Times. 39(8):1,12-12, April 25th, 2017. Favorites PDF Get Content & Permissions
Possible Combo Therapy for Treatment-Resistant Leukemia Less Oncology Times. 39(7):23, April 10th, 2017. Favorites PDF Get Content & Permissions
Richter's Transformation in Patients With CLL Parikh, Sameer A. Parikh, Sameer A. Less Oncology Times. 39(4):1,14,16-16, February 25th, 2017. Favorites PDF Get Content & Permissions
Treatment-Free Remission Consistent in CML Patients Who Switch to Nilotinib Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(3):36, February 10th, 2017. Favorites PDF Get Content & Permissions
CD22 CAR T-Cell Therapy Induces Remissions in Young ALL Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(3):35, February 10th, 2017. Favorites PDF Get Content & Permissions
Ponatinib Approved for Treatment of Chronic Myeloid Leukemia Less Oncology Times. 39(2):25, January 25th, 2017. Favorites PDF Get Content & Permissions
Fasting Kills Cancer Cells of Most Common Type of Childhood Leukemia Less Oncology Times. 39(2):18, January 25th, 2017. Favorites PDF Get Content & Permissions
From Practice to Research to Forge Better Therapies for Leukemia Laberta, Valerie Laberta, Valerie Less Oncology Times. 39(1):32-33, January 10th, 2017. Favorites PDF Get Content & Permissions
Cellular Immunotherapies for Leukemia Patients Maloney, David G.; Banker, Deborah E. Maloney, David G.; Banker, Deborah E. Less Oncology Times. 39(1):1,12-13, January 10th, 2017. Favorites PDF Get Content & Permissions
Long-Sought Genetic Model of Common Infant Leukemia Discovered Less Oncology Times. 38(23):16, December 10th, 2016. Favorites PDF Get Content & Permissions
Uncovering a New Subtype of Acute Lymphoblastic Leukemia Less Oncology Times. 38(23):1,16-16, December 10th, 2016. Favorites PDF Get Content & Permissions
The Genomic Landscape for Acute Myeloid Leukemia Less Oncology Times. 38(22):1,11-11, November 25th, 2016. Favorites PDF Get Content & Permissions
Novel Mechanism in Drug Combination Shows Potential for Treating Leukemia Less Oncology Times. 38(21):1,12-12, November 10th, 2016. Favorites PDF Get Content & Permissions
Prospect of Shorter Treatment & Cure for CML Less Oncology Times. 38(20):3, October 25th, 2016. Favorites PDF Get Content & Permissions
Umbilical Cord Blood Transplant in High-Risk Leukemia Patients Less Oncology Times. 38(19):37, October 10th, 2016. Favorites PDF Get Content & Permissions
Screening for Pregnancy in Young Patients With Leukemia Not Adequate Less Oncology Times. 38(19):34, October 10th, 2016. Favorites PDF Get Content & Permissions
Venetoclax Promising in Patients With Acute Myelogenous Leukemia Less Oncology Times. 38(17):33, September 10th, 2016. Favorites PDF Get Content & Permissions
Novel Drug Development in CLL & HNL Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(14):1,11,13-13, July 25th, 2016. Favorites PDF Get Content & Permissions
Is MRD Negativity Necessary for CLL Patients? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(13):34-35, July 10th, 2016. Favorites PDF Get Content & Permissions
Dexamethasone vs. Prednisone in Acute Lymphoblastic Leukemia Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(13):1,7-7, July 10th, 2016. Favorites PDF Get Content & Permissions
Look at Patient Needs Prior to CLL Initial Therapy Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(11):16-17, June 10th, 2016. Favorites PDF Get Content & Permissions
How Previous TKIs Affect Outcomes With Ponatinib DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 38(9):1,11-11, May 10th, 2016. Favorites PDF Get Content & Permissions
Study: BCR-ABL1 Mutations Not Drivers of Ponatinib Resistance DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 38(8):1,13,41-41, April 25th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Imbruvica (Ibrutinib for CLL) Less Oncology Times. 38(7):34, April 10th, 2016. Favorites PDF Get Content & Permissions
Antibody-TKI Combination Impairs Leukemia Stem Cells Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(7):19, April 10th, 2016. Favorites PDF Get Content & Permissions
Special Blood Product Requirements of Acute Promyelocytic Leukemia Draper, Nicole L. Draper, Nicole L. Less Oncology Times. 38(7):5-6, April 10th, 2016. Favorites PDF Get Content & Permissions
Improving Survival for Elderly With AML Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(7):1,3,6-6, April 10th, 2016. Favorites PDF Get Content & Permissions
Idelalisib-Rituximab Combo for CLL Kim, Meeri N. Kim, Meeri N. Less Oncology Times. 38(6):1,36-36, March 25th, 2016. Favorites PDF Get Content & Permissions
Venetoclax Granted Another FDA Breakthrough Therapy Designation—this Time for AML Less Oncology Times. 38(5):9, March 10th, 2016. Favorites PDF Get Content & Permissions
New Drugs Make Treatment of CLL Like a Chronic Disease Susman, Ed Susman, Ed Less Oncology Times. 38(5):36, March 10th, 2016. Favorites PDF Get Content & Permissions
Study Supports Role for Cancer Susceptibility Genes in Leukemia Risk among Breast Cancer Survivors Kilgore, Christine Kilgore, Christine Less Oncology Times. 38(5):22-23, March 10th, 2016. Favorites PDF Get Content & Permissions
How Genomic Data Are Changing the Leukemia Treatment Landscape Loo, Eric; De Abreu, Francine Blumental; Kaur, Prabhjot; More Loo, Eric; De Abreu, Francine Blumental; Kaur, Prabhjot; Ornstein, Deborah; Tsongalis, Gregory J. Less Oncology Times. 38(5):16-18, March 10th, 2016. Favorites PDF Get Content & Permissions
CML: BCR-ABL Transcript Type May Influence Survival Kim, Meeri N. Kim, Meeri N. Less Oncology Times. 38(5):1,6-6, March 10th, 2016. Favorites PDF Get Content & Permissions
FDA's Breakthrough Therapy Status to Venetoclax Combo Therapy for CLL Less Oncology Times. 38(4):9, February 25th, 2016. Favorites PDF Get Content & Permissions
How We Treat Patients with Chronic Myeloid Leukemia Jabbour, Elias; Kantarjian, Hagop M. Jabbour, Elias; Kantarjian, Hagop M. Less Oncology Times. 38(4):8-9, February 25th, 2016. Favorites PDF Get Content & Permissions
FDA Approves Bendeka (Bendamustine Hydrochloride) Injection for CLL and NHL Less Oncology Times. 38(3):33, February 10th, 2016. Favorites PDF Get Content & Permissions
In CML: Radotinib as Frontline Therapy; Ponatinib Promising for T315I Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(3):30-31, February 10th, 2016. Favorites PDF Get Content & Permissions
CML Patients Who Achieve Long-term Deep Molecular Response Can Stop Imatinib Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(3):29, February 10th, 2016. Favorites PDF Get Content & Permissions
CML: First-line Therapy with Dasatinib + Pegylated Interferon Induces Deep Molecular Responses Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):35, January 25th, 2016. Favorites PDF Get Content & Permissions
Dose Optimization of Nilotinib Boosts Molecular Response in CML Fuerst, Markl L. Fuerst, Markl L. Less Oncology Times. 38(2):34, January 25th, 2016. Favorites PDF Get Content & Permissions
ASH PLENARY STUDY: Targeted Agent Improves Survival in AML Patients with FLT3 Mutations Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):26-27, January 25th, 2016. Favorites PDF Get Content & Permissions
New Use for Rituximab: Addition to Chemotherapy in Adult ALL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):24-25, January 25th, 2016. Favorites PDF Get Content & Permissions
Targeted Therapies Show Impressive Results in Relapsed/Refractory CLL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):21-22, January 25th, 2016. Favorites PDF Get Content & Permissions
Best Leukemia Abstracts from ASH 2015 Kadia, Tapan M. Kadia, Tapan M. Less Oncology Times. 38(2):1,8-9, January 25th, 2016. Favorites PDF Get Content & Permissions
CML: New Drug Overcomes TKI Resistance in Heavily Pretreated Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(1):31-32, January 10th, 2016. Favorites PDF Get Content & Permissions
How We Treat Patients with Relapsed/Refractory AML Dinardo, Courtney D.; Ravandi, Farhad Dinardo, Courtney D.; Ravandi, Farhad Less Oncology Times. 37(24):14-15, December 25th, 2015. Favorites PDF Get Content & Permissions
Defining Who Benefits from HSCT in CML DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 37(23):27, December 10th, 2015. Favorites PDF Get Content & Permissions
Study: CML Monitoring Guidelines Not Consistently Followed in Community Setting Lindsey, Heather Lindsey, Heather Less Oncology Times. 37(23):9-10, December 10th, 2015. Favorites PDF Get Content & Permissions
FDA Priority Review to CLL and Myeloma Drugs Less Oncology Times. 37(22):62, November 25th, 2015. Favorites PDF Get Content & Permissions
AML Stem Cell Transplant Survival: Same for Haploidentical vs. Matched-Unrelated Kim, Meeri Kim, Meeri Less Oncology Times. 37(22):1,34-35, November 25th, 2015. Favorites PDF Get Content & Permissions
Nilotinib and High-Dose Chemotherapy Promising for Ph+ ALL Lindsey, Heather Lindsey, Heather Less Oncology Times. 37(21):34-35, November 10th, 2015. Favorites PDF Get Content & Permissions
AML/MDS Outpatient Care Post-Induction Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(20):1,29-29, October 25th, 2015. Favorites PDF Get Content & Permissions
Insights into How CML Stem Cells Resist Treatment Less Oncology Times. 37(18):52, September 25th, 2015. Favorites PDF Get Content & Permissions
FDA's Orphan Drug Status to Inecalcitol for AML Less Oncology Times. 37(17):10, September 10th, 2015. Favorites PDF Get Content & Permissions
New Insights into Deadly Form of ALL Less Oncology Times. 37(17):1,16-16, September 10th, 2015. Favorites PDF Get Content & Permissions
3 Questions on... Why ‘What's Old Is New’ in CML with Carlo Gambacorti-Passerini, MD DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 37(16):48, August 25th, 2015. Favorites PDF Get Content & Permissions
‘The Greatest Danger in CML’ Kim, Meeri Kim, Meeri Less Oncology Times. 37(16):1,14-15, August 25th, 2015. Favorites PDF Get Content & Permissions
POINT-COUNTERPOINT: CLL—What's the Best Frontline Therapy for Younger Patients? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(15):12-13, August 10th, 2015. Favorites PDF Get Content & Permissions
ASH-EHA Session on Companion Diagnostics as Key to Approval of New Cancer Drugs Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(6):36-38, March 25th, 2015. Favorites PDF Get Content & Permissions
Leukemia Researcher Hagop Kantarjian's New Grassroots Effort Against High Cancer Drug Costs Butcher, Lola Butcher, Lola Less Oncology Times. 37(4):1,37-38, February 25th, 2015. Favorites PDF Get Content & Permissions
Separating the Hope, Hype, and Reality of Precision Medicine Fuerst, Mark Fuerst, Mark Less Oncology Times. 37(3):1,16-18, February 10th, 2015. Favorites PDF Get Content & Permissions
Working to Improve Oral Chemotherapy Administration Butcher, Lola Butcher, Lola Less Oncology Times. 36(24):1,51-52, December 25th, 2014. Favorites PDF Get Content & Permissions
AACR Conference Highlights Promising Early Research on Blood Malignancies Samson, Kurt Samson, Kurt Less Oncology Times. 36(20):57-61, October 25th, 2014. Favorites PDF Get Content & Permissions
ASCO Survey Picks Top 5 Advances in Clinical Cancer Research in the Last 50 Years Less Oncology Times. 36(19):36, October 10th, 2014. Favorites PDF Get Content & Permissions
CML: Seeking Ways to Optimize Early Molecular Response Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 36(10):47, May 25th, 2014. Favorites PDF Get Content & Permissions
CML: Pros and Cons for Initial Therapy Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 36(9):10, May 10th, 2014. Favorites PDF Get Content & Permissions
CML Study Links Imatinib Copayments to Adherence to Treatment Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 36(4):1,14-15, February 25th, 2014. Favorites PDF Get Content & Permissions
New CML Registry to Better Understand Patients' Social and Emotional Needs Less Oncology Times. 35(24):16, December 25th, 2013. Favorites PDF Get Content & Permissions
The Ponatinib Problem: Debating the FDA's Recent Market Suspension DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 35(24):7-9, December 25th, 2013. Favorites PDF Get Content & Permissions
Will the Costs of Cancer Care Ever Come Down? Speakers at AACI Meeting Discuss the Nuances of the Question Eastman, Peggy Eastman, Peggy Less Oncology Times. 35(21):10-11, November 10th, 2013. Favorites PDF Get Content & Permissions
MUSINGS OF A CANCER DOCTOR: How Much Life? Sledge, George W. Sledge, George W. Less Oncology Times. 35(20):12-13, October 25th, 2013. Favorites PDF Get Content & Permissions
Post-Academia, Mace Rothenberg Reflects on His Five Years in Industry Rosenthal, Eric T. Rosenthal, Eric T. Less Oncology Times. 35(17):22-23, September 10th, 2013. Favorites PDF Get Content & Permissions
Books: ‘THE PHILADELPHIA CHROMOSOME A Mutant Gene and the Quest to Cure Cancer at the Genetic Level,’ by Jessica Wapner Young, Robert C. Young, Robert C. Less Oncology Times. 35(15):30-31, August 10th, 2013. Favorites PDF Get Content & Permissions
Survey Says: In CML, Imatinib Still Preferred Frontline Treatment for Newly Diagnosed Patients Fuerst, Mark Fuerst, Mark Less Oncology Times. 35(13):40-41, July 10th, 2013. Favorites PDF Get Content & Permissions
